BioIntelliSense Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
89
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$58.3M
- Investors
-
18
BioIntelliSense General Information
Description
Developer of a remote patient monitoring device designed to enhance healthcare delivery. The company's device provides continuous, passive monitoring of vital signs and biometrics through medical-grade wearable devices with actionable health insights and supporting early intervention, enabling healthcare providers to improve patient outcomes, streamline clinical workflows and reduce hospital readmissions.
Contact Information
Website
www.biointellisense.comCorporate Office
- 17301 West Colfax Avenue
- Suite 152
- Golden, CO 80401
- United States
Corporate Office
- 17301 West Colfax Avenue
- Suite 152
- Golden, CO 80401
- United States
BioIntelliSense Timeline
BioIntelliSense Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 01-Jun-2026 | $58.3M | Completed | Generating Revenue | ||
| 6. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B1) | 30-Dec-2022 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 28-Jul-2021 | Completed | Generating Revenue | |||
| 3. Grant | 24-Dec-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 08-Sep-2020 | $12M | $37M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 17-May-2019 | $25M | $25M | Completed | Generating Revenue |
BioIntelliSense Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B-1-1 | ||||||||
| Series B | ||||||||
| Series A-1 | 2,540,939 | $0.000100 | $0.38 | $4.72 | $4.72 | 1x | $4.72 | 7.85% |
| Series A | 9,999,066 | $0.000100 | $0.2 | $2.5 | $2.5 | 1x | $2.5 | 30.89% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BioIntelliSense Comparisons
Industry
Financing
Details
BioIntelliSense Competitors (52)
One of BioIntelliSense’s 52 competitors is Agatsa, a Venture Capital-Backed company based in Noida, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agatsa | Venture Capital-Backed | Noida, India | ||||
| Spacelabs Healthcare | Corporate Backed or Acquired | Snoqualmie, WA | ||||
| CardioDiagnostics | Private Equity-Backed | Campbell, CA | ||||
| CloudTag | Formerly PE-Backed | Kingstown, Saint Vincent | ||||
| ZOLL Medical | Corporate Backed or Acquired | Chelmsford, MA |
BioIntelliSense Patents
BioIntelliSense Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260080977-A1 | Biological programming language | Pending | 20-Jun-2024 | ||
| US-20250391498-A1 | Protein latent structure traversal | Pending | 20-Jun-2024 | ||
| US-20250378901-A1 | Protein refinement and joint optimization | Pending | 07-Jun-2024 | ||
| US-12367329-B1 | Protein binder search | Active | 06-Jun-2024 | ||
| US-20260161853-A1 | Protein binder search | Pending | 06-Jun-2024 | G06F30/27 |
BioIntelliSense Signals
BioIntelliSense Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Confluent | Corporation | |||
| Dexcom Ventures | Corporate Venture Capital | Minority | ||
| Fresenius Medical Care Ventures | Corporate Venture Capital | Minority | ||
| TLG Capital Management | PE/Buyout | Minority | ||
| Chimera Capital | PE/Buyout | Minority |
BioIntelliSense Acquisitions (1)
BioIntelliSense’s most recent deal was a Merger/Acquisition with AlertWatch. The deal was made on 18-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AlertWatch | 18-Oct-2022 | Merger/Acquisition | Decision/Risk Analysis |
BioIntelliSense Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| AlertWatch | Ann Arbor, MI | 2011 |
BioIntelliSense FAQs
-
When was BioIntelliSense founded?
BioIntelliSense was founded in 2019.
-
Where is BioIntelliSense headquartered?
BioIntelliSense is headquartered in Golden, CO.
-
What is the size of BioIntelliSense?
BioIntelliSense has 89 total employees.
-
What industry is BioIntelliSense in?
BioIntelliSense’s primary industry is Monitoring Equipment.
-
Is BioIntelliSense a private or public company?
BioIntelliSense is a Private company.
-
What is BioIntelliSense’s current revenue?
The current revenue for BioIntelliSense is .
-
How much funding has BioIntelliSense raised over time?
BioIntelliSense has raised $319M.
-
Who are BioIntelliSense’s investors?
Confluent, Dexcom Ventures, Fresenius Medical Care Ventures, TLG Capital Management, and Chimera Capital are 5 of 18 investors who have invested in BioIntelliSense.
-
Who are BioIntelliSense’s competitors?
Agatsa, Spacelabs Healthcare, CardioDiagnostics, CloudTag, and ZOLL Medical are some of the 52 competitors of BioIntelliSense.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process